Gabexate is a protease inhibitor indicated in the treatment of acute pancreatitis. Gabexate is a synthetic serine protease inhibitor which has been used as an anticoagulant.
- Mechanism
- Curator reviewed · 3 references
Gabexate inhibits kallikrein, plasmin, and thrombin by binding to their active sites. The inhibition of these components of the coagulation cascade ultimately prevents the formation of fibrin which must be present and polymerized to form a clot. Gabexate decreases the production of inflammatory cytokines by attenuating NFkappaB and c-Jun N-terminal kinase (JNK) pathway activity. The exact mechanism for this is unknown but it is thought that gabexate prevents the proteolyytic destruction of IkappaB which deactivates NFkappaB and interferes with activator protein 1 binding to DNA.
- Primary indication
- No approved indication.Curator reviewed · 2 structured indications
- Formula / weight
- C16H23N3O4 · 321.377 g/mol (avg)
Resolves to
YKGYIDJEEQRWQH-UHFFFAOYSA-NSMILESCCOC(=O)C1=CC=C(OC(=O)CCCCCNC(N)=N)C=C1What you can answer from here — as of September 13, 2026
Which drugs share a target with Gabexate, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account